Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05267080
Other study ID # RESPECT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 25, 2023
Est. completion date January 2028

Study information

Verified date August 2023
Source Cardiovascular and Interventional Radiological Society of Europe
Contact Claire Poulet, PhD
Phone +43 664 54 20 433
Email respect@cirse.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The Registry on Percutaneous ElectroChemoTherapy (RESPECT) is a post-market, prospective, non-randomized, observational study aiming at evaluating the effectiveness of percutaneous electrochemotherapy (ECT) for the treatment of liver cancer.


Description:

Electrochemotherapy (ECT) is a local tumour ablation technique that uses reversible electroporation to transiently permeabilize the cell membrane in order to increase the cytotoxicity of chemotherapeutic drugs. A major advantage of ECT is that its antitumour efficacy is driven by the chemotherapeutic agent which predominantly targets rapidly-dividing tumour cells, with very little collateral damage on neighbouring structures. ECT is typically performed using the CLINIPORATOR®, a medical grade pulse generator for clinical electroporation, whose development was funded by the European Commission in an effort to standardize the operating procedures for ECT. The feasibility, safety and efficacy of ECT with the CLINIPORATOR® have been consistently reported for the management of different types of primary and secondary liver cancers: colorectal liver metastasis, hepatocellular carcinoma, portal vein tumour thrombosis from hepatocellular carcinoma, perihilar cholangiocarcinoma and liver metastasis from renal cancer. While ECT for liver malignancies has been mostly performed intraoperatively, recent studies have successfully used a percutaneous approach. These studies, which were either single-case reports or involved a very limited number of patients (< 10), have introduced percutaneous ECT as a very promising minimally invasive treatment option for liver cancer, with the obvious benefits of fewer surgical complications, faster recovery and shorter hospitalization. However, results from a larger and more diverse patient population are needed in order to confirm its therapeutic efficacy. The aim of the RESPECT study is to expand our understanding of percutaneous ECT for primary and secondary liver cancer by 1) substantiating the evidence base for the effectiveness and safety of percutaneous ECT in a large-scale, multi-centric, cross-border sample; and 2) extending the current evidence base regarding percutaneous ECT with appropriately defined follow-up data, as well as information regarding quality of life. RESPECT is a post-market, prospective, non-randomized, observational study. Patients with any type of liver cancer will be given the possibility to enrol after they are referred to percutaneous ECT by a multidisciplinary tumour board, hence participation to the registry neither affects treatment plan nor influence treatment quality. Patient enrolment will last 2 years, with a follow-up period of maximum 3 years. Data will be collected less than 1 week before treatment (baseline) and at different intervals following treatment (1 day, 2 weeks, 1 month, 3 months, 6 months, 12 months, and every 6 months until the end of the study). Effectiveness of ECT will be primarily assessed by the status of each treated lesion 12 months after ablation. Overall survival, overall local disease-free survival, hepatic disease-free survival, time to untreatable progression by ECT and vacation from systemic cancer therapy will give further insight into the impact of ECT. Safety will be evaluated based on the occurrence and severity of adverse events associated with the treatment. Quality of life and pain will be documented using questionnaires filled by the patients at the first 3 to 4 follow-ups. Overall, RESPECT intends to provide healthcare professionals and health authorities with information on percutaneous ECT for liver cancer to help decision-making regarding treatment access and treatment modalities and optimize patient care.


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date January 2028
Est. primary completion date January 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Primary or secondary liver cancer - Signed informed consent form - Referral to local ablative treatment by multidisciplinary tumour board and decision to use ECT by treating interventional radiologist - ECT treatment with CLINIPORATOR Exclusion Criteria: Pregnancy

Study Design


Intervention

Device:
CLINIPORATOR
The CLINIPORATOR is used to perform percutaneous electrochemotherapy on liver tumours.

Locations

Country Name City State
Germany University Hospital Regensburg Regensburg

Sponsors (1)

Lead Sponsor Collaborator
Cardiovascular and Interventional Radiological Society of Europe

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local Tumour Control Based on the tumour status according to mRECIST assessment 12 months
Secondary Safety (in terms of adverse events related to treatment) Based on the occurrence of adverse events and their severity according to CTCAE v5.0 12 months
Secondary Tumour status (size) Based on tumour size End of study (maximum 36 months)
Secondary Tumour status (mRECIST) Based on mRECIST assessment End of study (maximum 36 months)
Secondary Quality of life (EORTC QLQ-C30) Based on the Quality of Life questionnaire EORTC QLQ-C30 filled by the patients before ECT treatment and at different time intervals following ECT treatment.
Quality of life data is measured according to three scales: functional scale, symptom scale and global health. On the functional scale, scores range from 1 to 4, with a score of 1 corresponding to no at all and a score of 4 corresponding to very much. On the symptom scale, scores range from 1 to 4, with a score of 1 corresponding to no at all and a score of 4 corresponding to very much.
For global health, the scores range from 1 to 7, with a score of 1 corresponding to either very poor global health or very poor quality of life, and a score of 7 corresponding to either excellent global health or excellent quality of life.
3 months
Secondary Pain assessment Based on the pain questionnaire filled by the patients before ECT treatment and at different time intervals following ECT treatment.
Severity of pain is graded on a scale from 0 to 10, with 10 corresponding to the most severe pain. Pain frequency is graded from 0 (no pain) to 4 (chronic pain persistent for more than 3 months). Quality of pain is classified into 4 categories: no, somatic, visceral and neuropathic pain.
1 month
Secondary Effectiveness (Survival) Survival will be categorized with respect to overall survival, overall local disease-free survival and hepatic disease-free survival End of study (maximum 36 months)
Secondary Effectiveness (Time to untreatable progression by ECT) Based on the timeframe until the progressing tumour is not treatable by ECT anymore End of study (maximum 36 months)
Secondary Systemic cancer therapy vacation Based on the time frame following ECT treatment during which patients do not need systemic cancer therapy End of study (maximum 36 months)
Secondary Economic aspects Based on the duration of hospitalization following ECT treatment 2 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03161925 - Chinese Liver Cancer Clinical Survey N/A
Completed NCT00261378 - Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation Phase 2
Enrolling by invitation NCT05609448 - MRI-guided Holmium-166 Radioembolization N/A
Recruiting NCT05714124 - Liver Embolization Approaches for Tumor Management
Not yet recruiting NCT05353894 - Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers Phase 1
Completed NCT03518632 - Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer (APACHE) N/A
Terminated NCT00003530 - Antineoplaston Therapy in Treating Patients With Primary Liver Cancer Phase 2
Recruiting NCT04806464 - Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer Phase 1
Recruiting NCT06342414 - An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Completed NCT01116804 - Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC) Phase 1
Recruiting NCT03067493 - RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial Phase 2
Completed NCT05183776 - Clinical Validation of a Fractional Administration Device for Holmium-166 SIRT N/A
Not yet recruiting NCT06430983 - Recurrent Liver Cancer: Reconceptualization and Reevaluation
Recruiting NCT05677724 - Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment
Not yet recruiting NCT03178929 - Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma N/A
Not yet recruiting NCT02327819 - The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer N/A
Completed NCT01640522 - Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms N/A
Completed NCT00408122 - Evaluation of Preoperative Investigations in Patients With Liver Cancer N/A
Recruiting NCT03297255 - Primary Liver Cancer Cohort of South China N/A
Recruiting NCT06325267 - Clinical Characteristics of Primary Liver Cancer